Global Strategic Fund, L.P.... Net Worth

The estimated Net Worth of Global Strategic Fund, L.P.... is at least $2.14 million dollars as of 22 October 2021. Global P owns over 615,702 units of Metacrine stock worth over $1,209,249 and over the last 3 years Global sold MTCR stock worth over $929,710.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Global P MTCR stock SEC Form 4 insiders trading

Global has made over 1 trades of the Metacrine stock since 2021, according to the Form 4 filled with the SEC. Most recently Global sold 615,702 units of MTCR stock worth $929,710 on 22 October 2021.

The largest trade Global's ever made was selling 615,702 units of Metacrine stock on 22 October 2021 worth over $929,710. On average, Global trades about 615,702 units every 0 days since 2021. As of 22 October 2021 Global still owns at least 2,443,421 units of Metacrine stock.

You can see the complete history of Global P stock trades at the bottom of the page.

Insiders trading at Metacrine

Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.

What does Metacrine do?

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Complete history of Global P stock trades at Metacrine

Metacrine executives and stock owners

Metacrine executives and other stock owners filed with the SEC include:

• Dr. Preston S. Klassen M.D., M.H.S.,
  Pres, CEO & Director
• Dr. Preston S. Klassen,
  Pres, CEO & Director
• Patricia M. Millican,
  Chief Financial Officer
• Catherine C. Lee,
  Consultant
• Michael B. York,
  Chief Bus. Officer
• Theresa Lowry,
  VP of HR
• Patricia Millican,
  Chief Financial Officer
• Andrew Guggenhime,
  Director
• Jeffrey David Jonker,
  Director
• John G Mc Hutchison,
  Director
• Venture Fund Viii, L.P.Arch...,
  
• Kristina Burow,
  Director
• Preston Klassen,
  Director
• Enterprise Associates 16, L...,
  
• Trisha Millican,
  Chief Financial Officer
• Forest Baskett,
  10% owner
• Ali Behbahani,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ronald M Evans,
  Director
• Carmen Chang,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Amir Nashat,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Joshua Makower,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Paul Edward Walker,
  10% owner
• Global Strategic Fund, L.P....,
  
• Robert J Adelman,
  
• Hubert C Chen,
  Chief Medical Officer
• Catherine Chai Zon Lee,
  EVP, Gen. Counsel & Secretary
• Julia C. Owens,
  Director
• Richard A. Heyman,
  Director
• Global Strategic Fund, L.P....,
  
• Michael York,
  Chief Business Officer
• Braden Michael Leonard,
  10% owner